$34.15 7.7%
CRSP Stock Price vs. AI Score
Data gathered: March 31

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Crispr Therapeutics (CRSP)

Analysis generated February 22, 2025. Powered by Chat GPT.

Crispr Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases. Based on CRISPR/Cas9 technology, the company pioneers next-generation gene-editing platforms aimed at curing genetic disorders. The wide application of CRISPR technology in healthcare can revolutionize how diseases are treated, making Crispr Therapeutics a potential game changer in the biotech industry.

Read full AI stock Analysis

Stock Alerts - Crispr Therapeutics (CRSP)

company logo Crispr Therapeutics | March 31
Price is down by -9.4% in the last 24h.
company logo Crispr Therapeutics | March 25
Insider Alert: Kulkarni Samarth is continuing selling shares
company logo Crispr Therapeutics | March 25
Business Outlook among employees is down by 8.7% over the last month.
company logo Crispr Therapeutics | March 19
Insider Alert: Prasad Raju is selling shares

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.


Crispr Therapeutics
Price $34.15
Target Price Sign up
Volume 2,920,000
Market Cap $3.17B
Year Range $34.15 - $58.5
Dividend Yield 0%
Analyst Rating 50% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q4 '2436M18M18M-37M-60M-0.440
Q3 '24600,00017M-17M-86M-105M-1.010
Q2 '24520,00019M-19M-126M-146M-1.490
Q1 '24500,00018M-17M-117M-136M-1.430
Q4 '23201M16M185M89M74M1.100

Insider Transactions View All

KASINGER JAMES R. filed to sell 81,729 shares at $41.2.
March 24 '25
Prasad Raju filed to sell 16,767 shares at $41.2.
March 24 '25
Bruno Julianne filed to sell 10,544 shares at $41.2.
March 24 '25
Kulkarni Samarth filed to sell 195,085 shares at $41.2.
March 24 '25
Prasad Raju filed to sell 12,714 shares at $41.8.
March 18 '25

What is the Market Cap of Crispr Therapeutics?

The Market Cap of Crispr Therapeutics is $3.17B.

What is the current stock price of Crispr Therapeutics?

Currently, the price of one share of Crispr Therapeutics stock is $34.15.

How can I analyze the CRSP stock price chart for investment decisions?

The CRSP stock price chart above provides a comprehensive visual representation of Crispr Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Crispr Therapeutics shares. Our platform offers an up-to-date CRSP stock price chart, along with technical data analysis and alternative data insights.

Does CRSP offer dividends to its shareholders?

As of our latest update, Crispr Therapeutics (CRSP) does not offer dividends to its shareholders. Investors interested in Crispr Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Crispr Therapeutics?

Some of the similar stocks of Crispr Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.